Pipeline Overview

Pipeline Overview

We have a robust drug development pipeline at various clinical and pre-clinical stages with the two most advanced indications expected to file NDAs in China in early 2019 for CIN and first half of 2019 for NSCLC, and in the U.S. in second half of 2019 for CIN and 2020 for NSCLC.